Literature DB >> 6165456

Combined modality therapy of esophageal carcinoma.

D P Kelsen, R Ahuja, S Hopfan, M S Bains, C Kosloff, N Martini, P McCormack, R B Golbey.   

Abstract

One hundred ten patients with epidermoid carcinoma of the esophagus were treated at the Memorial Sloan-Kettering Cancer Center (MSKCC) with combined modality techniques involving preoperative irradiation (RT) and surgery, and with preoperative chemotherapy (CT), surgery, and irradiation. For the 76 patients receiving preoperative RT during the period 1965-1976, the overall resectability rate was 54% with an operative mortality of 12%; long-term survivors (greater than 3 years) were few (7%). For 34 patients receiving preoperative CT with cisplatin and bleomycin, major objective tumor regression (greater than 50%) was seen by day 18 in 20%, with an additional 44% having smaller but definite improvement in the barium esophagram and in swallowing function. Of those receiving preoperative CT, 76% had resectable lesions, with an operative mortality of 11%. The median follow-up for this group is 24 months; of the 30 patients followed for at least 12 months, 20% are alive without evidence of disease. Although the resection rate following preoperative chemotherapy seems to be higher, thus allowing better palliation, neither preoperative radiation nor chemotherapy with cisplatin and bleomycin have had a major impact on long-term survival.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6165456     DOI: 10.1002/1097-0142(19810701)48:1<31::aid-cncr2820480108>3.0.co;2-4

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  The value of preoperative radiotherapy in esophageal cancer: results of a study of the E.O.R.T.C.

Authors:  M Gignoux; A Roussel; B Paillot; M Gillet; P Schlag; J P Favre; O Dalesio; M Buyse; N Duez
Journal:  World J Surg       Date:  1987-08       Impact factor: 3.352

Review 2.  Update in cancer chemotherapy: gastrointestinal cancer, cancer of the small intestines, gallbladder, liver, and esophagus.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1986-08       Impact factor: 1.798

Review 3.  Adjuvant therapies for cancer of the thoracic esophagus.

Authors:  T Nishihira; T Nakano; S Mori
Journal:  World J Surg       Date:  1994 May-Jun       Impact factor: 3.352

4.  Postoperative long-term immunochemotherapy for esophageal carcinoma. 5 year survival.

Authors:  Y Okudaira; K Sugimachi; K Inokuchi; H Kai; H Kuwano; H Matsuura
Journal:  Jpn J Surg       Date:  1982

Review 5.  Multimodality treatment of cancer arising from Barrett's epithelium.

Authors:  J A Roth
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

6.  Carcinoma of the esophagus in blacks.

Authors:  E B Smith
Journal:  J Natl Med Assoc       Date:  1985-01       Impact factor: 1.798

7.  A retrospective study on radiotherapy and radiochemotherapy in esophageal cancer.

Authors:  C M Kim; W S Hong; J O Lee; T W Kang; Y H Kim; C G Cho; K H Koh; S Y Yoo
Journal:  Korean J Intern Med       Date:  1988-01       Impact factor: 2.884

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.